Case Report of Dramatic Resolution of Psychotic Symptoms During Cross-Over to Clozapine by Sher, Leo, M.D. & Mendelowitz, Alan, M.D.
Case Report of Dramatic Resolution of
Psychotic Symptoms During Cro ss-over to
Clozapine
Leo Sher, M.D. and Alan Mendelowitz, M.D.
Abstract
Clozapine is thefirst antipsychotic drug with proven superiority overconventional antipsychot-
ics in the management oftreatment-resistant patients. vVe describe a case oftreatment-resistant
schieoaffectioe disorder in a y oung woman who improved rapidly on clozapine. The patient was
started on a low dose ofclozapine whilefluphenaeine was decreased. She improved significantly
during thefirst several days oftreatment. This improvement tookplace well before the expected ifJect
ofclozapine. Possible explanations fo r this unusual response include: J) the placebo ifJect; 2)
fluphena zine dose-response curve; 3) acute clorapine neurochemical mechanisms; 4) inaccurate
original diagnosis. Better understanding ofthe mechanisms ofaction ofantipsychotic drugs may
considerably improvepatient care.
C loza pine is th e first a n t ipsycho tic agent wit h proven superior ity over conven-
tional a n t ipsyc ho tics in term s of its efficacy in t reatment- resist ant patie nts (1,2). In
patients with poor or partial response to conve ntional neu rolep t ics, cloza pine is th e
treatment of choice . We wish to rep ort a nd to discuss a cas e of the rapid a nd
subs ta n t ia l improvement of a patient who was started on c1ozapine.
PRESENTI IG PROBLEM AND PATIENT DESCRIPTION
Ms. C. was a 34 year old whit eJewish fem ale with 13 yea r hist ory of schizoaffec-
tive disorder. At th e tim e of admission th e patient reported a ud itory hallu cin a t ions,
refer entia l delusions (the patient felt that other peop le were mak ing refe rence to
her), a nd th e bel ief that sh e was abl e to read th e minds of peopl e a round her. T he
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patient also reported sad mood a nd some a nx ie ty. She was tea rful with a constricted
affect. Ms. C. showed good insight int o her illn ess (she was aware of her illn ess, a nd
underst ood th at her sym pto ms a nd socia l probl em s were du e to her own dist ur-
bances), and expressed a strong desi re to ge t rid of her sym ptoms. This, desp it e the
fact th at th e male voice whi ch was " ta lking to her" sounded fri endly. (She s ta ted that
th e ability to hear this voice was abnormal.) During th e ini t ia l in terview Ms. C. also
displ ayed some dep endent features including th e need s for he r parents to assume
res pons ibility for decision s in her life. We had a n opportunity to in terview the
patient 's parents a nd learned th at th e patient always had dep end ent traits.
BACKGRO UND INFORMATION
Ms. C. did well academically in th e Elementary,junior Hi gh , an d High Schools.
Sh e skipped two school years and gradua te d from th e Hi gh Schoo l in 10 yea rs instead
of 12 years. Sh e entere d th e College, a nd she was close to comple t ing her Bachelor
Degr ee, when at th e age of 21, Ms . C. developed psychotic sympto ms includ ing
auditory hallucin ation s and ideas of referen ce. Her level of funct ion ing declin ed
considerably, and th e patient had to drop out of th e College . T he patien t was
hospitali zed on ce a t th e time of her fir st break , and th en she has bee n in out pa tient
treatment for 13 yea rs . The course of her illn ess was somewhat unusual : it wen t for 13
years fro m onset to th e first considera ble rel ap se. She has been on ha loperi dol for a
long ti me with a part ial res ponse (the level of her social fun cti oni ng was low, and,
some times, she had mild psych ot ic sym pto ms) . Six months prior to admission, th e
pa ti ent 's condit ion det eriorat ed , she developed persist ent a ud itory hallucinations
a nd referential delu sion s, and she was switched from haloperidol to fluphen azine.
Fluphenaz ine was gradua lly incr eas ed to 40 mglday. However, th e clinica l response
was temporary a nd limited . The pat ien t cont inue d to det e riorate, and her psychia-
t r ist referred her to th e hospital for inpatient t rea tm en t.
HOSPITAL COU RSE
Ms. C. was eva lua te d a nd felt to meet criteria for nonresponse to sta ndard
a ntipsyc hotic treatment , and was offered clozapine t reatment. She was told tha t
cloz apine was a very effec t ive drug, it helped many patients, who were part ial
responders , and that it could improve th e patient 's qu ality of life. Ms. C. ag reed with
cons idera ble en thusiasm. On th e fir st day of th e t reatment she received 12.5 mg of
clozapine wh ile fluph en azin e was tap ered to 20 mg. On the next day the pa tient
reporte d improvement, s ta ting th at her a udito ry hallucin ations were less d isturbing,
a nd th at she was free of th e hallucin ations for two hou rs in th e morning. On the fifth
day of th e treatment , when th e clozapine dose was 25 mg bid a nd fluph enazine dose
cont inued a t 20 rng/d ay, Ms. C. reported marked im prove me nt, the patient stated
th at she felt mu ch better, tot all y free fro m referential ideas. She rep orted that the
hallucin atory voice was quiet , less distu rbing, a nd a pa rt of the day she d id not hear it
a t all. She a lso felt reli ef from a nxie ty. Over th e following days Ms. C. reported
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improvement almost every day, sh e tol erated cloza pine well, and three wee ks after
her admission she was discharged with very conside rable improvem ent. At th e time of
discharge patient was not getting fluphenazine, and her clozapine dose was 200
mg/day.
DISCUSSION
This quick and remarkable response to cloza pine treatment in thi s patient
requires further evalua t ion. It can be expla ined in part by a placeb o effect which is
probably involved in every therapeutic maneuver. A number of fact or s whic h may
predict a good response in this patient may include th e patient 's stron g desi re to get
better, relatively good insight into her illness, a relatively high level of ed ucation, the
patient's high degree of suggestibility, th e pr esen ce of dep endent personal ity fea-
tures , th e desire to be a "good patient ," a nd th e fact th at th e med icat ion was given by
ca ring and confide nt physicians could cont ribute to thi s effect.
The "placebo effec t" is an outstanding example of mind-body re la t ions hips, a
case of transformation of psychological effec ts into biological processes (3,4) . Pa t ien ts
with schizophrenia may respond to placebos (5-8) . A st riking dep endence on a
placebo in a periodically catatonic schizophrenic wom an has been re por ted in th e
lit erature (5). An un expected placebo response was found during a double-blind drug
study in a patient with treatment-resistant tardive diskinesia (6). Schulz and col-
leagues reported an exce ssive beta-endorphin response to placebo in schizophren ic
patients (7) . Pickar and associates found incr eas es in plasma opi oid ac tivity after the
intravenous administration of placebo in patients with schizophre nia (8).
In 1978 Levine and associates who stud ied th e analge sic effec t of placebo
proposed that endorphin rel eas e medi ates a pla cebo respons e (9). Several studies
were conduc te d to test th e hypothesis that beta-endorphins are endogenous sub-
st an ces with neuroleptic-like activity and th at disturbances in th e bet a-endorphin
fra gm entation may contribu te to th e pathogen esis of psychotic disord ers (10-12).
These studies showed th at endorphins ca n poss ess neuroleptic pr operties. Hence, it
ca n be argued th at placebo may cause a rel eas e of endoge nous subs ta nces with
neuroleptic-like activity and produce an antipsychotic effec t.
Decr eas e in fluphenazine dos e could also play a part in th e pa ti ent 's quick and
substantial improvement. Clinical information on th e th erapeutic dosage of antipsy-
chot ics remains controversial. It has been proposed that neuroleptics may have a
bell-shaped dos e-response curve (13). Possibly, in this ca se 20 mg of fluphenazine per
day could give a better clinical response than 40 mg/day. It is also possible that
decr ease in fluph enazine caused reduction in ex tra pyramidal symptoms, and th e
improvement was from the decreas e in th ese symptoms.
Another possible expla na t ion can be connec te d with monoamine and amino acid
transmission in different brain regions after ac ute cloza pine administ rat ion . The
expe rime nts on ra ts showed that the acute administration of 10- 30 mg/ kg of
cloza pine increased dopamine and glutamate in th e medial pr efrontal cortex, and
produced a gr eater incr ease compa red with haloperidol, in ga mma-aminobutyric ac id
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efflux within the ventral pa llidum (14). These changes were obs erved 1- 2 hou rs after
the clozapine administration. Combined dysfunction of dopamine and N-m et hyl-D-
aspartate glutamate receptors with th e involvem ent of GABAergic neurons has been
implicated in pathophysiological mechanism of sch izophrenia, a nd it has been
suggested tha t som e antipsychotic drugs , including c1ozapine, ca n pr eve nt th ese
pat ho logical changes in the br ain (I5).
There is a possibility that th e original diagnosis was inaccurate. The unusual
course of th e patient 's illn ess (it went for 13 years from ons et to fir st serious rela pse)
and the unusually rapid improvement aft er th e inpatient adm issio n migh t be rela ted
to th e incorrect original di agnosis.
CONCLUSION
Over th e past de cad es we have witnessed con sid erab le pro gr ess in th e psychophar-
macological treatment of psychotic disorders. Antipsych oti c medi cat ions help man y
patients. Better understanding of th e mech anisms of ac tion of psych otropic drugs
may significantly improve patient care .
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